Humana Inc. (NYSE:HUM) Shares Sold by Estabrook Capital Management

Estabrook Capital Management trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 8.4% in the second quarter, Holdings Channel reports. The firm owned 596 shares of the insurance provider’s stock after selling 55 shares during the period. Estabrook Capital Management’s holdings in Humana were worth $223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. increased its position in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the last quarter. Hantz Financial Services Inc. acquired a new stake in Humana in the 2nd quarter valued at approximately $35,000. Family Firm Inc. acquired a new stake in Humana in the 2nd quarter valued at approximately $37,000. Hollencrest Capital Management acquired a new position in Humana during the second quarter worth $40,000. Finally, Riverview Trust Co purchased a new position in shares of Humana during the second quarter worth $44,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Baird R W upgraded Humana to a “hold” rating in a report on Thursday, May 30th. Morgan Stanley started coverage on shares of Humana in a research note on Monday, June 24th. They set an “equal weight” rating and a $374.00 price target on the stock. Robert W. Baird assumed coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price target on the stock. Oppenheimer lifted their price objective on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Thirteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $398.70.

Humana Price Performance

HUM stock opened at $310.41 on Friday. The business has a 50 day moving average price of $357.71 and a 200 day moving average price of $345.61. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The stock has a market cap of $37.40 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.56 and a beta of 0.50. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the prior year, the business posted $8.94 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Equities research analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.14%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s payout ratio is currently 22.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.